Search
Displaying 391–400 of 665 for “retinitis clinical trial”
-
Urine Test Helps Diagnose RP Caused by DHDDS Mutations
Research NewsWhile it isn’t a substitute for a diagnosis through genetic testing, the urine test can verify that a given DHDDS mutation is, in fact, causing RP.
-
When a Condition is More than a Retinal Disease
Research NewsThe Foundation Fighting Blindness is, of course, all about finding treatments and cures for retinal degenerative diseases. However, we are well aware that many of our constituents and their families are dealing with more than just vision loss. That’s because genetic defects causing retinal conditions can sometimes affect other parts of the body. The result is conditions often referred to as syndromes.
-
Researcher Revolutionized Fight Against Blindness and Cancer
Research NewsA profile on Dr. Robert Langer, a medical researcher who has received dozens of awards, accolades and honorary degrees, including, recently, FFB’s Visionary Award.
-
Why Face Recognition Can Be Difficult with Central Vision Loss
Research NewsDiseases such as age-related macular degeneration, cone-rod dystrophy and Stargardt disease cause scotomas, or blind spots, which often have devastating effects on central vision. They cause gaps in a person’s visual field, making it difficult to see words in a book, images on a computer monitor or TV and the features of someone’s face.
-
Beacon Stories
The parents of young children affected by retinal diseases walk a fine line – between making the best of a trying situation and preparing for the worst.
-
ProQR Announces Virtual Presentations at Scientific Conferences
ResourceProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt).
-
Full Transcript - 2019 Investing in Cures Summit - March 2, 2019
Full Session Transcripts of the 2019 Investing in Cures Summit.
-
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
Foundation NewsThe Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
Proceed with Caution as Cell-Based Retinal Disease Therapies Show Promise.
In recent years, the number of stem cell treatments offered by various clinics claiming to benefit retinal eye disease has increased. Of concern, are those clinics administering stem cell-based therapies that do not adhere to the U.S. Food and Drug Administration’s (FDA) standards. Recently, a federal court ruled that the FDA has regulatory authority over stem cell procedures and has the power to halt them, even if the stem cells originate from the participating patient.
-
Virtual Workshop on Inflammation in Viral Gene Therapy of the Retina
This workshop was designed to bring together industry and academia to discuss openly what is known about the interactions of viral-mediated gene therapy of the retina with the immune system and the clinical consequences of that.
